Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Unknown 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 18INDUSTRY 5NIH 3

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 158Gastrointestinal 130Dermatologic 117Genitourinary 92Head & Neck 52Other solid neoplasm 44Breast 34Gynecologic 32Tumor-Agnostic 28Lymphoid 21CNS 17Sarcoma 8Other hematologic neoplasm 7Plasma cell 5Endocrine 5Myeloid 3Other neoplasm 1NET 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Melanoma 2Adrenocortical Carcinoma 2Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Mesothelioma 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Nivolumab × Endocrine × Clear all
NCT04187404 2026-01-30

Spencer

Enterome

Phase 1/2 Terminated
70 enrolled 20 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT03647163 2025-09-16

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Vyriad, Inc.

Phase 1/2 Active not recruiting
33 enrolled
EndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Neuroendocrine

NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Purple Biotech Ltd.

Phase 1/2 Completed
79 enrolled
DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05266612 2024-08-09

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Virogin Biotech Ltd.

Phase 1 Recruiting
12 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Infinity Pharmaceuticals, Inc.

Phase 1 Unknown
219 enrolled
BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡